देश: ऑस्ट्रेलिया
भाषा: अंग्रेज़ी
स्रोत: Department of Health (Therapeutic Goods Administration)
atorvastatin calcium, Quantity: 20.68 mg (Equivalent: atorvastatin, Qty 20 mg)
Southern XP IP Pty Ltd
Atorvastatin calcium
Tablet, film coated
Excipient Ingredients: titanium dioxide; pregelatinised maize starch; colloidal anhydrous silica; activated attapulgite; magnesium stearate; hyprolose; hypromellose; lactose monohydrate; macrogol 4000; microcrystalline cellulose
Oral
30
(S4) Prescription Only Medicine
An adjunct to diet for the treatment of patients with hypercholesterolaemia. Prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated. Hypertensive patients with multiple risk factors for CHD which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic CHD (see Actions, Clinical trials, Prevention of cardiovascular disease) to reduce the risk of nonfatal MI and nonfatal stroke. These effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.
Visual Identification: white, oval, biconvex tablets with a breakline on one side and dimensions 12.7 mm x 6.7 mm and 4.6 mm in thickness; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 27 Months; Container Temperature: Store below 25 degrees Celsius
Licence status A
2013-07-01